Reasearch Awards nomination

Email updates

Keep up to date with the latest news and content from Nutrition Journal and BioMed Central.

Open Access Highly Accessed Research

Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial

Bor-Jen Lee1, Yu-Fen Tseng2, Chi-Hua Yen345 and Ping-Ting Lin26*

Author Affiliations

1 The Intensive Care Unit, Taichung Veterans General Hospital, Taichung 40705, Taiwan

2 School of Nutrition, Chung Shan Medical University, Taichung 40201, Taiwan

3 Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan

4 School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan

5 Center for Education and Research on Geriatrics and Gerontology, Chung Shan Medical University, Taichung 40201, Taiwan

6 Department of Nutrition, Chung Shan Medical University Hospital, Taichung 40201, Taiwan

For all author emails, please log on.

Nutrition Journal 2013, 12:142  doi:10.1186/1475-2891-12-142

Published: 6 November 2013

Abstract

Background

High oxidative stress and chronic inflammation can contribute to the pathogenesis of coronary artery disease (CAD). Coenzyme Q10 is an endogenous lipid-soluble antioxidant. Statins therapy can reduce the biosynthesis of coenzyme Q10. The purpose of this study was to investigate the effects of a coenzyme Q10 supplement (300 mg/d; 150 mg/b.i.d) on antioxidation and anti-inflammation in patients who have CAD during statins therapy.

Methods

Patients who were identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery and who were treated with statins for at least one month were enrolled in this study. The subjects (n = 51) were randomly assigned to the placebo (n = 24) and coenzyme Q10 groups (Q10-300 group, n = 27). The intervention was administered for 12 weeks. The concentrations of coenzyme Q10, vitamin E, antioxidant enzymes activities (superoxide dismutase, catalase, and glutathione peroxidase), and inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6)] were measured in the 42 subjects (placebo, n = 19; Q10-300, n = 23) who completed the study.

Results

The levels of the plasma coenzyme Q10 (P < 0.001) and antioxidant enzymes activities (P < 0.05) were significantly higher after coenzyme Q10 supplementation. The levels of inflammatory markers (TNF-α, P = 0.039) were significantly lower after coenzyme Q10 supplementation. The subjects in the Q10-300 group had significantly higher vitamin E (P = 0.043) and the antioxidant enzymes activities (P < 0.05) than the placebo group at week 12. The level of plasma coenzyme Q10 was significantly positively correlated with vitamin E (P = 0.008) and antioxidant enzymes activities (P < 0.05) and was negatively correlated with TNF-α (P = 0.034) and IL-6 (P = 0.027) after coenzyme Q10 supplementation.

Conclusion

Coenzyme Q10 supplementation at 300 mg/d significantly enhances antioxidant enzymes activities and lowers inflammation in patients who have CAD during statins therapy.

Trial registration

Clinical Trials.gov Identifier: NCT01424761.

Keywords:
Coenzyme Q10; Statins; Antioxidation; Inflammation; Coronary artery disease